Inventiva S.A.
Inventiva S.A. (IVEVF): 1 pipeline candidate. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Inventiva S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$848.0M
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| iva337 | Phase 3 |
Frequently asked questions
How many drug candidates are in Inventiva S.A.'s pipeline?
Inventiva S.A. (IVEVF) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inventiva S.A.'s lead drug candidate?
Inventiva S.A.'s most advanced tracked candidate is iva337 (Phase 3) for NASH - Nonalcoholic Steatohepatitis.
What is Inventiva S.A.'s market capitalization?
Inventiva S.A.'s market capitalization is approximately $848.0M.
Who is the CEO of Inventiva S.A.?
Mr. Andrew Obenshain is the chief executive officer of Inventiva S.A. (IVEVF).
Get the full picture on Inventiva S.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.